Shares of drug firm Granules India

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

today surged over 6 per cent after the company said it has

received Establishment Inspection Report (EIR) from the US

health regulator for the OmniChem facility at Vizag, Andhra

Pradesh.

The stock soared 6.37 per cent to end at Rs 121.85 on

BSE. During the day, it jumped 7.20 per cent to Rs 122.80.

At NSE, shares of the company rose by 6.19 per cent to

settle at Rs 121.80.

The company's market valuation went up by Rs 472.16 crore

to Rs 3,092.16 crore.

In terms of equity volume, 8.12 lakh shares of the

company were traded on BSE and over 98 lakh shares changed

hands at NSE during the day.

OmniChem facility is operated by 50:50 joint venture of

Granules India and Ajinimoto OmniChem N V, it said in a filing

on BSE.

"This facility was inspected by the USFDA in December

2016 and there were seven observations during the inspection.

The facility manufactures Active Pharmaceutical Ingredients

(API) intermediates," Granules India said.

 

(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)